Clostridium difficile Infection: Is It Finally Time to Give Mom Vancomycin?
Infectious Diseases in Clinical Practice July 2016 V.24 N.4 P.193–194
Gallagher, Jason C.
From the Department of Pharmacy Practice, School of Pharmacy, Temple University, Philadelphia, PA.
Despite the long-term availability of 2 primary and familiar options, the pharmacotherapy for Clostridium difficile infections (CDI) has evolved along an interesting path. Vancomycin enjoyed a time at the top of the armamentarium, though it was initially used due to the thought that Staphylococcus aureus was the cause of pseudomembranous colitis.1 When C. difficile was determined to be the true cause of disease in 1978, vancomycin was known to be active and had already demonstrated efficacy in the treatment of CDI.2 However, 2 primary factors prompted the search for a substitute therapy: the cost of commercially available oral vancomycin, and concerns that oral vancomycin use is associated with infection from vancomycin-resistant enterococci (VRE).3–5 From a microbiological, tolerance, and cost perspective, metronidazole was a logical choice……
PDF (CLIC in PDF)
Entry filed under: Antimicrobianos, Bacterias, Biología Molecular, Epidemiología, Health Care-Associated Infections, Infecciones gastrointestinales, Infecciones nosocomiales, Metodos diagnosticos, REPORTS, Sepsis, Update. Tags: .